Projected lives saved and economic value of mRNA cancer immunotherapies in the United States
Assessment of the potential public health and economic value of mRNA immunotherapies as cancer treatments and outcomes for non-small cell lung cancer, pancreatic cancer, renal cell carcinoma, and metastatic melanoma finds the economic value is substantially exceeding the funding cut and highlighting the long-term value...